clinical pipeline
Application of S1P1 receptor
agonists to additional
immune-medicated diseases
Sequestration of self-reactive T and B lymphocytes and prevention of their trafficking to sites of inflammation is a mechanism of action that can be exploited for the treatment of other autoimmune diseases, including Crohn's disease, psoriasis, and lupus. The Receptos portfolio of proprietary S1P1 agonist compounds, including RPC1063, contains candidates that exhibit diverse molecular and therapeutic profiles that may be used to fully exploit the therapeutic potential of the class.